Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page 1of23
Security Classification: Confidential
Author: JorisAHdeGroot
lnCs:ClinicalStudySpecialist
Company:
Sponsor’s LegalEntity:
Business:
Department:Philips
PhilipsMedicalSystems Nederland B.V.
Veenpluis 4
5684PCBest
TheNetherlands
Document ID:
Date:
Revision:
Status:XCY610-130253
2018Apr06
2.0
Approved
APPROVAL
—Date(yyyyMondd)
/
20gaç” 6
‘“Post-Market ClinicalStudyPlan
Multicenter observational cohortstudytoevaluate
Cerebral AneurysmFlow Results inOcclusion (CARO)
IGTSystems
ClinicalScience
Name
BartCarelsen
JorisAHdeGroot
IngeJenniskens
loanaUleaFunction
lnCs:ClinicalStudy
Specialist Manager
lnCs:StudyLeader
lnCs:ClinicalStudy
Specialist
Q&R:RAofficer
FormID:XCT-0302018 revO6f2016Feb01 PtiliIps’proprietary Information, unauthorized useisprohibited
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page2of23
REVISION HISTORY
Date Rev.Author Changes/Comments
2018Jan09 1.0JorisARdeGroot Initialversion
2018Mar132.0JorisARdeGroot Removed 3monthfollow-up tobetter
resemble currentclinicalpractice
Updated approvalstatusinparticipating
countries
Addedextramotivation forthe
multicenter natureofthestudy
Minorcorrection toFlowchart
UpdatedSection10Compliance
Statement tosecurecompliance forall
participating centers.
FormID:XCT.0302018 revOGI2016Feb01 Philipsproprietary information. Unauthorized useisprohibited
Philips Post-Market ClinicalStudyPlan XCY610-130253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page3of23
TABLEOFCONTENTS
APPROVAL 1
REVISION HISTORY 2
TABLEOFCONTENTS 3
SUMMARY 5
1.DEVICE DESCRIPTION 8
1.1.Summary description ofthestudydevice 8
1.2.Intended Purpose 9
1.2.1. MedicalPurpose 9
1.2.2. PatientPopulation 9
1.2.3. ClinicalEnvironment 9
1.3.Necessary trainingandexperience neededtousetheresearch device 9
1.4.Materials thatwillbeincontactwithtissuesorbodyfluids 9
1.5.DeviceTraceability 10
2.JUSTIFICATION FORTHEDESIGN OFTHESTUDY 10
2.1.ClinicalstudyJustification 11
3.OBJECTIVES ANDHYPOTHESES 11
3.1.Primaryobjective 11
3.2.Secondary objectives 11
3.3.Exploratory objectives 11
4.STUDYDESIGN 11
4.1.General 11
4.2.Studydeviceexposure 12
4.3.Subjects 12
4.3.1. In-andexclusion criteria 12
4.3.2. Enrollment andduration 12
4.3.3. Numberofsubjects 12
4.3.4. Subjectwithdrawal ordiscontinuation 12
4.4.Procedures 13
4.5.Monitoring Plan 15
5.STATISTICAL CONSIDERATIONS 16
5.1.SampleSizeJustification 16
5.2.GeneralConsideration 16
5.3.Subjectdisposition 16
5.4.Primaryobjective 16
5.5.Secondary objectives 17
5.5.1. Secondary objective: Predictive valueat6monthsfollow-up 17
5.5.2. Secondary objective: Optimal MAFAratiothreshold 17
5.5.3. Secondary objective: Adverseevents 17
5.6.Exploratory objectives 18
5.6.1. Exploratory objective: Potential valueadditional AneurysmFlow parameters 18
5.6.2. Exploratory objective: Potential ValueofAddingClinicalVariables 18
6.DATAMANAGEMENT 18
6.1.Retention period 19
7.AMENDMENTS TOTHECLINICAL STUDYPLAN 19
8.DEVIATIONS FROMTHECLINICAL STUDYPLAN 19
9.DEVICE ACCOUNTABILITY 19
10.STATEMENTS OFCOMPLIANCE 19
11.INFORMED CONSENT PROCESS 20
11.1.Subjectunabletoreadorwrite 20
FormIDXCT-0302018 revo6/2016Feb01 Philipsproprietary Information. Unauthorized useIsprohibited.
Philips Post-Market ClinicalStudyPlan XCY6IO-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page4of23
12.SAFETY REPORTING 20
13.EARLYTERMINATION ORSUSPENSION OFTHECLINICAL STUDY 20
14.PUBLICATION POLICY 21
15.ABBREVIATIONS USED 21
16.REFERENCES 21
APPENDIX ILISTOFINVESTIGATORS ANDSITES 22
APPENDIX II:LISTOFMONITOR(S)/CLINICAL SCIENTIST 23
FarmDXCT-0302018 rev0612016 Feb01 Philips’proprietary information. Unauthorized useIsprohibited.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
ICTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page5of23
SUMMARY
Identification ofstudydevice
AneurysmFlow Ri.0isanapproved (CElabeled,cleared inUS,CanadaandArgentina), software tool
intended toproviderelevantinformation onthebloodflowinacerebralaneurysm anditsparentartery
basedonangiography. Itprovides colorcodedandvectorfieldrepresentation ofadigitalsubtraction
angiography (DSA). ItcanquantifybloodflowratesinthearterybasedonDSAand3-DRotational
Angiogram (3DRA)data.Itcanvisualize bloodflowpatterns inananeurysm basedonDSAdata.
Specifically, itcalculates theMeanAneurysm FlowAmplitude (MAFA)ratiotomeasure thevolumetric flow
ratequotientbeforeandafterFlowDiverterStent(FDS)implantation intheregionofinterest.
Itismanufactured byPhilipsMedicalSystemsBy.,aPhilipsHealthcare company.
Studydesign
Thisisaprospectively planned, singlearm,observational, multicenter cohortstudytoassessthe
prognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 12monthsafterflowdiverter
placement.
Objectives
Primaryobjective;
•Toassesstheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 12
monthsafterflowdiverterplacement.
Secondary objectives:
•Toassesstheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 6months
afterflowdiverterplacement.
•Todetermine optimalMAFAratiothreshold.
•Toregister(serious)adverseevents(i.e.re-operations, rupturesanddeaths).
Exploratory objectives:
•Toevaluate thepotential valueofadditional AneurysmFlow parameters forpredicting full
aneurysm occlusion 6and12monthsafterflowdiverterplacement.
•Toevaluate thepotential valueofadditional clinicalvariables topredictfullaneurysm occlusion 6
and12monthsafterflowdiverterplacement usingmultivariate logisticregression.
Primaryandsecondary endpoints
Theprimaryendpoint istheprognostic value(i.e.c-statistic including confidence intervals) oftheMAFA
ratiowithrespecttofullaneurysm occlusion (i.e.usingtheRaymond-Roy Occlusion Classification Ion
standard-of-care headimaging) 12monthsafterFlowDiverterStentplacement. Secondary endpoints are
theprognostic value(i.e.c-statistic including confidence intervals) oftheMAFAratiowithrespecttofull
aneurysm occlusion onstandard-of-care headimaging 6monthsafterflowdiverterplacement, theoptimal
threshold fortheMAFAratioandthenumberofadverseevents.
Maininclusion criteria
•Subjectwithunruptured, 5rnmsaccularaneurysm(s) locatedintheanteriorintracranial
circulation andsuitableforanendovascular treatment withaFlowDiverterStent
•Subject is18yearsofageorolder,oroflegalagetogiveinformed consentperstateornational
law
•Subject isavailable forclinicalfollow-ups
Mainexclusion criteria
•Non-saccular brainaneurysm(s) (i.e.,dissecting, fusiform, atherosclerotic, mycotic, bifurcational)
Prioraneurysm treatment witheitherendovascular (stenting, coiling)orsurgical(clipping)
techniques
•Endovascular treatment assisted withcoilsorintracranial stents
•Significant orsevereallergytointra-arterial contrastmediumuncontrolled bypre-procedure
medications
•Severekidneydisease(e-GFR <60)
FormIDXCr.0302018 revOGI2016Feb01 PbUJpsproprfetary Information. Ijnauthoriied useIsprohibited.
Philips Post-Market ClinicalStudyPlan XCY610-130253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page6of23
.Subjects notwilling(orable)toattendpostFDSinsertionstandard-of-care followupclinicvisits
requiring DSA,headMRIorCTAimaging
.Subjectparticipates inapotentially confounding drugordevicetrialduringthecourseofthestudy.
.Subjectmeetsanexclusion criteriaaccording tonationallaw(e.g.age,pregnant woman,breast
feedingwoman)
No.ofsubjects
Intotal120subjects willbeenrolled inthestudy.Theenrollment periodisexpected tolastfor1year.
Studyprocedures
Physician investigators participating inthisstudyareexpected tofollowtheirnormalclinicalpractice in
enrolling, treatingandfollowing patientswithintracranial aneurysms thatareamenable totreatment with
flowdiverterstents,Noadditional procedures arerequired ofpatients inordertoparticipate inthis
observational study.
Pre-Screening
Patientspresenting withintracranial saccularaneurysm(s) willbeevaluated bytheneurointerventional
team,inaccordance withinstitutional practice, toestablish anappropriate treatment planbasedonthe
patient’s medicalcondition andavailable diagnostic screening procedures priortorecruitment inthestudy.
Morethanoneaneurysm inasinglepatientmaybetreated,butonlythetargetaneurysm(s) treatedwith
FDSdevicesinitiallywillbeconsidered aspartofthisstudy.Iftreatment oftheaneurysm withtheEDSis
deemedappropriate, theinstitution’s guidelines regarding theirethicscommittee andinformed consent
process willbefollowed.
Screening
Afterobtaining theconsentform(s)approved bythelocalresearch ethicsboard(REB),theprincipal
investigator willscreenthepotential investigation subjects fortheCARDstudy.Theprincipalinvestigator
orhisdelegates onthestudyteamwillenterdatainapre-designed e-CRF.Thiswillincludepatient
demographics, relevantpastmedicalandsurgicalhistory,andspecifictargetaneurysm dataalongwith
pre-procedural/screening imagingdetails.
Onlypatientswhomeetallinclusion andnoneoftheexclusion criteriawillqualifyforthisstudy.The
measurement andsizeofeachaneurysm willbeverifiedbytheprincipal investigator. Ifthesizeofthe
aneurysm isacceptable, thenitwillbeincluded inthestudy.Itisrecommended thatthismeasurement
shouldbedonewithin180daysbeforetheprocedure.
IndexProcedure andDischarge
Theinvestigator willproceed withstandard ofcareprocedures onthedayofIndexProcedure (i.e.FDS
insertion) forthetargetaneurysm(s). Then,endovascular treatment procedure detailsshouldbeprovided
underthe“INDEXPROCEDURE &DISCHARGE” fieldforeacheligiblepatient.
Bloodflowvelocity willbecalculated usingthededicated software AneurysmElow (PhilipsHealthcare,
Best,TheNetherlands), whichwillbeinstalled onstandard ofcareimagingequipment. Forthispurpose,
digitalsubtraction angiograms willbeacquired duringtheprocedure; justbeforeandrightafterplacement
oftheFDS.
Calculation ofbloodflowvelocity willbeperformed automatically ontheAneurysmFlow software. The
operator willhaveaccesstotheresultsofthecalculation inadditiontoalloftheregularinformation thatis
athis/herdisposal duringroutineclinicalpractice.Therearenoadditional devicesormedications required
forthestudy.TheAneurysmFlow softwareusesstandard-of-care 2DDSAand3D-RAimagesequences
todetermine thisflowinformation. Allrawimagesequences willbestoredforfuturereference.
Figure 1showstheworkflow forusingtheAneurysmFlow software inthisstudy.
FormID:XCT.0302015 revo6/2016 Feb01 Philips’proprielary rifomiallon. unauhozed useisprohibited
Instep1a3Drotational angiogram (SD-RA) willbeperformed intheneuro-interventional suitewiththex
rayC-armtoacquirea3Dimagevolumeoftheaneurysm anatomy tobetreated.Fromthis3D-RA,an
optimalviewinganglefortheC-armwillbedetermined toobtaingoodflowinformation. Thisangleshould
showtheparentartery,aneurysm neckandaneurysm itselfclearlywithoutanyoverlap.The3D-RAwill
alsohelptodetermine agoodC-armviewingangletohelppositionanddeploytheFDSacrossthe
aneurysm.
InStep2a2DDSAx-rayrunwithcontrastagentinjection (i.e.advisedinjectionrate1.5to2cc/s)willbe
acquired attheoptimalC-armviewingangledetermined bythe3D-RAscantoobtaindynamic blood
motioninformation beforeFDSdeployment atthelocationoftheaneurysm. Iftheinitialcontrastagent
injectionwasinsufficient, theinjection willbealteredandrepeated withanotherDSAruntoobtainhigh
qualityimageinformation. TheFDSwillthenbeplacedatthelocationoftheaneurysm.
InStep3,afterFDSdeployment, asecondDSArunwithcontrastagentwillbeacquired (i.e.injectionrate
=1.5to2ccfs)attheoptimalC-armviewingangledetermined fromthe3D-RAtoqualitatively evaluate
bloodmotionintheregionoftheaneurysm afterdeployment oftheFDS.TheC-armangleandinjection
rateofthissecondDSArun(postFDSdeployment) mustbethesameasthefirstDSArun(preFDS
deployment). The2DSArunsandthe3D-RAimagevolumewillautomatically besenttothe
AneurysmFlow workstation rightaftertheyareacquired. IftheFDSisballooned afterplacement, the
physician isaskedtorepeatStep3afterballooning.
InStep4aroutineVasoCTscan,whichisanother3Drotational x-rayC-armscan,willthenbeperformed
withthex-rayC-armintheneuro-interventional suitetoevaluate the3Dapposition ofthedeployed FDS
withrespectthevesselwall.
Theregionofinterestaroundtheaneurysm andthecorresponding arterialsegment fromwhichithas
developed willbeautomatically segmented bytheAneurysmFlow software, butmanualcontrolsare
available inthesoftware ifmodifications totheanatomical segment ofinterestaredesiredbythe
interventionalist. Thesemodifications canbeperformed byanappropriately trainedstudymember. The
software willthenautomatically calculate theflowparameters oftheaneurysm bothbeforeandafterFDS
deployment, alongwiththeMAFAratio.
Forthisstudy,theoperator willhavethechoiceofselecting whichtargetaneurysms areamenable toFDS
treatment. Patientsthathavesingleormultipletargetaneurysms thataresuitableforFDStreatment asa
firsttreatment stepwouldbeacceptable forthisstudy.Eachtargetaneurysm inthepatientwillhavea
separate CRFsub-form tofillout.Additionally, eachtargetaneurysm sub-form canbefurtherdividedinto
severalFDSsub4orms toaccountformultipleflowdiverters, ifneeded.Tosummarize, ifthepatienthas
morethanonetargetaneurysm and/orneedsmorethanoneflowdiverterperaneurysm, thenasub4orm
ontheCRFwillneedtobefilledoutforeachaneurysm andforeachFDSused.
AsshowninFigure1,ifatargetaneurysm istreatedwithaFDS(ormorethanone)initially,andisthen
treatedusinganotherapproach (suchascoiling)thenthistargetaneurysm canremainincludedaspartof
thestudy.However, ifatargetaneurysm istreatedusinganon-FDS approach initially(suchaswithPhilips Post-Market ClinicalStudyPlan XCY610-130253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page7of23
Step3:DSA Step4:vaso-a
HighsiocDSAverilythelocation
ofthestent
AneurysmFow
ProFlowbisector
placement
L_iflow/MAFAL_J
analysis
FormID:XCT.O3O2DlarevO6l 2016Feb01 Philips’proprietary information. Unauthorized useIsprohibited.
Follow-up visitStartvisitwindow Targetdate Endvisitwindow
(dayspost-procedure) (dayspost-procedure) (dayspost-procedure)
6-months 134 183 225
12months 316 365 414
Adverse Events
All(serious) adverseevents(i.e.re-operations, rupturesanddeaths)whetherornotrelatedtothe
investigational devicewillbecollected andreported conform localrulesandregulations.
Followup
Thesubjects willbefollowed-up at6and12monthsaccording toregularclinicalstandard ofcare.
Duration ofthestudy
Thetotalduration ofthestudyisexpected totakeapproximately 2.5years.Patientenrollment willtake
placebetween March2018andSeptember 2019.Eachsubjectwillbeinthestudyfor1year(follow-up).
1. DEVICE DESCRIPTION
1.1.Summary description ofthestudydevice
AneurysmFlow Ri.0isanapproved (CElabeled,cleared inUS,CanadaandArgentina), software tool
intended toproviderelevantinformation onthebloodflowinacerebralaneurysm anditsparentarterybased
onangiography. Itprovides colorcodedandvectorfieldrepresentation ofadigitalsubtraction angiography
(DSA).ItcanquantifybloodflowratesinthearterybasedonDSAand3-DRotational Angiogram (3DRA)
data.Itcanvisualize bloodflowpatterns inananeurysm basedonDSAdata.
Specifically, itcalculates theMeanAneurysm FlowAmplitude (MAFA)ratiotomeasure thevolumetric flow
ratequotientbeforeandafterFlowDiverterStent(FDS)implantation intheregionofinterest.
Itismanufactured byPhilipsMedicalSystemsBy.,aPhilipsHealthcare company.
Whentreatingintracranial aneurysms, neuro-interventionalists areinterested intheflowpatternsinsideand
aroundthoseaneurysms becausetheseflowpatternsarelikelytoimpactthenaturalevolution ofaneurysms,
suchasgrowthandriskofrupture. Inordertoevaluate theflow,physicians usehighspeedangiograms. By
FormIDXcT-0302015 revaG?2016Feb01 Philipsproprietary information. Unauthorized useIsprohibited.Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page8of23
coiling),followed byplacement ofanFDSorotherapproach, thentheaneurysm willbeexcluded fromthe
study.
TheMAFAratiowillbecalculated aftertheplacement ofeachFDS.ForeachFDS,thisratiowillbe
determined withtheflowinformation beforeanystentswereplacedandalsowiththeflowinformation after
eachFDSwasplaced.ThefinalMAFAratiowillbecalculated usingtheflowinformation beforeanyFDS
deviceswereplacedandusingtheflowinformation afterthelastFDSwasplaced.Clinicalandimaging
outcomes ofaprocedure willbeassessed usingacombination oftheflowmetricscalculated bythe
AneurysmFlow software available totheoperator duringinterventional treatment inaddition toinformation
thatisroutinelyacquired duringFDSplacement. Thisinformation acquiredacrossthepatientpopulation in
thestudywillalsocontribute todetermine marepreciseMAFAratiothresholds toimproveprediction of
complete aneurysm occlusion afterFDSplacement. Thisstudywillnotmakeanyrecommendation on
patientmanagement orontreatment strategy. Also,thissoftware willnotdisruptstandard-of-care
workflow fortheinterventionalist.
Follow-Ups (6and12months)
AllregistrypatientstreatedwithFDSareexpected tofollowtheirroutineposttreatment clinicalvisits,
whichwillincludeastandard-of-care headimaging(e.g.CTA,MRAand/orDSA)testtoclassifyaneurysm
occlusion (i.e.Raymond-Roy Occlusion Classification I(Royetat,1997))at6months(±49days)and12
months(±49days).Duringthe6and12monthfollowupvisits,patientmedicalchartswillbeaccessed to
collectadverseevents(ifapplicable) anddocument anypost-treatment neurological deterioration
(neurological assessment, mRsscale).De-identified data(i.e.clinicalnotes,imagingreportsetc.)willbe
entered intherelevante-CRFsections.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page9of23
observing andanalyzing thedisplacement anddispersion oftheinjectedcontrasttheydevelopan
understanding andcanmeasure therateofthebloodflow.
TheAneurysm FlowVisualization optionservestoextractandenhance theflowpatterns fromthosehigh
speedangiograms, assisting thephysician intheobservation andanalysis ofthesepatterns.
Aneurysm FlowVisualization doesnotchangethebasicfunctionality oftheInterventional Workspot and/or
theinterventional X-raysystem.Usersneedtoadheretothenormalhandlingandsafetyprecautions as
mentioned intheIFU.
Thestudydeviceincludes asoftwarereleasenumbertopermitfullidentification.
Themanufacturer ofthestudydeviceis:
PhilipsMedicalSystems Nederland B.V.
Veenpluis 4-6
5684PCBest
TheNetherlands
1.2.Intended Purpose
AneurysmFlow isasoftware toolintended toproviderelevantinformation onthebloodflowina
cerebralaneurysm anditsparentarterybasedonangiography.
AneurysmFlow isasoftware medicaldeviceandisintended tobeusedincombihation withaPhilips
interventional X-raysystemand3Drotational angiogram (SD-RA)data.
AneurysmFlow isasoftware product(Interventional Tool)thatprovides colorcodedandvectorfield
representation ofadigitalsubtraction angiography (DSA). Itcanquantitybloodflowratesinthearterybased
onDSAand3D-nAdata.Itcanvisualize bloodflowpatterns inananeurysm basedonDSAdata.Itcanalso
provideasidebysidevisualandquantitative comparison between twoacquisitions.
1.2.1.MedicalPurpose
AneurysmFlow assistsduringendovascular procedures fortreatingofsaccularcerebralaneurysms, by:
-Visualization ofbloodflowpatterns intheaneurysm andparentvessel,basedonDSA.
-Quantification ofthebloodflowintheaneurysm parentvessel,basedonDSAand3D-RA.
-Comparison ofbloodflow,bothvisualandquantified between twoacquisitions.
1.2.2.PatientPopulation
AneurysmFlow issuitableforusewithpatientswhowereelectedforacerebralendovascular aneurysm
treatment procedure usingfluoroscopy.
Thestudydevicemanualcontainssafetyprecautions andhandling ofthestudydevice.
1.2.3.ClinicalEnvironment
Aneurysm Flowisintended tobeusedinthecontrolroomandintheexamroomofaninterventional
suiteorhybridoperating room.Thesystemisconnected toaPhilipsInterventional X-raysystem.
1.3.Necessary training andexperience neededtousetheresearch device
TheIntended Operator profileisaclinicalspecialist whoisfullyskilledandresponsible forsoundclinical
judgment andforapplyingthebestclinicalprocedure, forexample (butnotlimitedto):interventional
neuroradiologists, skilledradiology technicians (ornurses)assisting thephysician,
vascular/endovascular/neuro surgeons.
1.4.Materials thatwillbeincontact withtissuesorbodyfluids
Nomaterials ofthestudydevicewillbeincontactwithtissueorbodyfluids.
FormlDXcT.030201 8revo6/2016Feb01 Philipsproprietary Information. Unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY610-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page10of23
1.5.DeviceTraceability
Thestudydeviceincludes aname,including software versionandaccessories topermitfullidentification.
Devicetraceability willbemaintained byPhilips.Records shallbekepttodocument whenthedeviceis
received, installed oruninstalled atthehospital.
2.JUSTIFICATION FORTHEDESIGN OFTHESTUDY
Intracranial aneurysms IA(s)areaprevalent medicalcondition forwhichtheirrupturecanproduce amajor
impactinapatient’s lifeandalsoinsocietybecause ofcollective costsassociated withdisability recovery,
treatment andrehabilitation (Brunoetat,1998).Thephysiopathology ofIA(s)isstillundefined andthereis
nocorresponding animalmodeltobetterstudyandunderstand thedisease(Brunoetat,1998).Treatment
ofIA(s)progressed overtheyearswithadvances inthesurgicalfieldandthedevelopment ofminimally
invasivetechniques (Kringsetat,2011).Thisprogress generated amajorimpactonclinicalpracticesuchas
thedevelopment ofcoilembolization withorwithoutballoonremodeling, intracranial stentassisted coiling
andmorerecently, implantation offlowdiverting stent(FDS)devices(Pereiraatat,2013).AnFDSisan
endoluminal prosthesis thatchanges theintra-aneurismal flowandprogressively replaces itwiththrombosis
untilthewholeaneurysm isexcluded frombloodcirculation, alongwithparentvesselremodeling (Lylyket
at,2009).Thistechnology broughtasignificant advance totheneuroradiology fieldandsomeimportant
questions startedtoberaisedconcerning itsmodeofuse,efficacy,procedural risks,postprocedural
bleeding riskandtimetakentocomplete aneurysm thrombosis aftertreatment (Lylykatat,2009).The
evaluation ofthisnewtechnology remainsuncertain, butoverthepastyears,manydiscussions andmeeting
sessions havebeendedicated tointracranial hemodynamics andaneurysmal flow.
Anewmethod todetermine intracranial flowfromx-raydigitalsubtracted angiography (DSA)imagesduring
endovascular treatment procedures hasbeendeveloped. ThismethodformsthebasisofthenewPhilips
AneurysmFlow visualization software usedfortheproposed research inthisprotocol.Themethod isbased
onopticalflowanalysis toestimate velocityvectorsfrombothtemporal andspatialvariations ofcontrast
agentdensity,measured from2Dtime-series DSAimages(Bonnefous atat,2012).
2.2DatafromPre-Clinical Studies
Thetechnique behindtheAneurysmFlow software isbasedontheacquisition of2DDSAsequences, in
combination witha3Drotational angiography (3D-RA) acquisition. Theseimageacquisitions arealreadypart
ofroutine,standard-of-care imagingforbrainaneurysm patients. UsingtheAneurysmFlow software, the
proposed technique measures theflowvaluesfromanangiographic DSAsequence. Itexploitsthe
transportation ofcontrastagentinjectedintothearterialbloodstream.Duetothepulsatilecharacter ofthe
bloodflow,contrastmediapatternsarecreatedthatpropagate inthevascular network. Usingimage
processing techniques, velocityprofilesareobtained fromthemotionofthesepatterns. Finally,thevelocity
profilesareconverted intoflowvalues.Tovalidatetheapproach described above, ithasbeentestedusing
vascularphantoms. Inaninvitrosetup,X-raybasedflowestimations werecompared toflowvaluesrecorded
byflowmeters.Furthermore, variouscontrastmediuminjectionprotocols wereexplored todetermine the
appropriate injectionparameters. Theresultsoftheinvitrotestssuggested thattheproposed technique can
beusedinroutineclinicalconditions withstandard imageacquisition protocols (Bonnefous atat,2012).
2.3ClinicalExperience
Theclinicalfeasibility ofthetechnique mentioned aboveusingAneurysmFlow waspreviously evaluated
usingseveralclinicalcasesacquired duringinterventional procedures. Thisworkcompared Doppler
ultrasound flowmeasurements withX-raybasedflowmeasurements. Theoutcomes ofthesetests
suggested thattheuseoftheAneurysmFlow software isfeasibleduringinterventional procedures
(Bonnefous atat,2012).Furthervalidation ofthetechnique wasperformed onasetof22clinicalcases
(Pereiraatat,2014).Duringthatstudy,bloodflowvelocity intheinternalcarotidarterymeasured using
AneurysmFlow wasvalidated withDopplersonography. Meanflowratesmeasured withtheAneurysmFlow
methodsignificantly matched Dopplersonography measurements (sloperegression coefficient, b083 ±
0.19,P0.05).Theseinitialresultsprovedthatbloodflowvelocitymeasurements canbemeasured reliably
andaccurately usingtheAneurysm Flowsoftware.
TheAneurysmFlow softwarehasalsobeenusedforpatientspresenting withsaccularunruptured lAs,to
assessbothflowmodification afterFDSimplantation andcorrelation withaneurysm thrombosis. Ametrichas
beendefined,theMeanAneurysm FlowAmplitude (MAFA)ratio,tomeasure thevolumetric flowrate
quotientbeforeandafterFDSimplantation intheregionofinterest.Thoughpreliminary, thisMAFAratio
FormID:XCT-0302D15 revOC!2016Feb01 Philips’proprietary Information, unauthorized useisprohibited
•Philips Post-Market ClinicalStudyPlan XCY610-130253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page11of23
indexpredicted thrombosis accurately withcommercialized flowdiverterstents.Thiswasthefirsttimeblood
flowcouldbeappraised inin-vivointracranial vesselsduringendovascular procedures (Pereiraata!.,2013).
Recently, alargerstudyconducted bythecoordinating investigator confirmed theseresults(notyet
published).
2.1.ClinicalstudyJustification
Previously published datahasindicated thatbloodflowchangesmeasured bytheAneurysm Flowsoftware
predicted thrombosis accurately withcommercialized FlowDiverting Stents(FDS).(Pereira etat,2014)The
purpose oftheclinicalstudyinthisprotocol istoinvestigate theabilityoftheintra-operative, intra-aneurysmal
flowevaluation toassistwiththetreatment ofintracranial aneurysms 5mmusingFDS.
Theclinicalhypothesis ofthisprotocoltobetestedisthatbyknowingthepotential aneurysm occlusion rates
bycalculation oftheMAFAratioduringaprocedure, onemightbeabletoadaptthetherapeutic strategy
intra-operatively tomaximize theflowdiverting effectforinducingcomplete aneurysm occlusions. Different
strategies canbeusedtoaccelerate theaneurysm occlusion suchastheadditionofanotherstentlayeror
stent-assisted coilingwithajailedmicro-catheter. Currenttreatment strategies arebasedonpersonal
physician preferences oronsubjective evaluation ofaneurysm stagnation.
Inthisprotocol, wepropose totestamorequantitative assessment oftheintra-aneurysmal flow,whichmay
beabletosupportintra-operative clinicaldecisions whichimprovetheocclusion rateofIA(s)afterFDS
treatment. Additionally, datacollected inthisproposed studywillfurtherexpandthebodyofclinical
knowledge concerning therelationship between bloodflowmetrics(including butnotlimitedtotheMAFA
ratio)asdetermined bytheAneurysmFlow software andclinicaloutcome inpatientsundergoing treatment
forintracranial aneurysms withFDS.
3.OBJECTIVES ANDHYPOTHESES
3.1.Primaryobjective
Theprimaryobjective ofthisclinicalstudyis:
•Toassesstheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 12months
afterflowdiverterplacement.
3.2.Secondary objectives
Thesecondary objective are:
•Toassesstheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 6months
afterflowdiverterplacement.
•Todetermine optimalMAFAratiothreshold.
•Toregister(serious)adverseevents(i.e.re-operations, rupturesanddeaths).
3.3.Exploratory objectives
Theexploratory objectives are:
•Toevaluate thepotential valueofadditional AneurysmFlow parameters forpredicting fullaneurysm
occlusion 6and12monthsafterflowdiverterplacement.
•Toevaluate thepotential valueofadditional clinicalvariables topredictfullaneurysm occlusion 6
and12monthsafterflowdiverterplacement usingmultivariate logisticregression.
4. STUDYDESIGN
4.1.General
Thisisaprospectively planned, singlearm,observational, multicenter cohortstudytoassesstheprognostic
valueoftheMAFAratioforpredicting fullaneurysm occlusion 12monthsafterflowdiverterplacement.
Aprospective observational multi-center studyhasbeenchosentoobservestandard ofcarewiththestudy
device.Themulti-center natureofthestudywillnotonlyenablemoreefficientpatientenrollment andthusa
FormID:XCT.0302018 revD6I2016Feb01 Philips’proprietary information. Unauthorized useIsprohibited,
Philips Post-Market ClinicalStudyPlan XCY610-130253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page12of23
shorterstudyduration, butitwillalsoprovideinformation onheterogeneity betweencentersandenable
(cross)validation ofstudyresults.
4.2.Studydeviceexposure
Thisisanobservational study,inwhichdataiscollected duringtheregularclinicalprocedure: atreatment of
ananeurysm with(a)flowdiverter(s). Duringthisprocedure, high-speed angiograms willbemadebeforeand
afterplacement oftheflowdiverterdevice.Clinicaldecision making isnotaffected bythisstudy.
Therearenoadditional devicesormedications required forthestudy.
4.3.Subjects
4.3.1. In-andexclusion criteria
Subjects participating inthestudywillbecarefullyselectedbasedonthenextinclusion andexclusion
criteria.
4.3.1.1. Inclusion criteria
•Subjectwithunruptured, Smmsaccularaneurysm(s) located intheanteriorintracranial circulation
andsuitableforanendovascular treatment withaFlowDiverterStent
•Subject is18yearsofageorolder,oroflegalagetogiveinformedconsentperstateornationallaw
•Subjectisavailable forclinicalfollow-ups
4.3.1.2. Exclusion criteria
•Non-saccular brainaneurysm(s) (i.e.,dissecting, fusiform, atherosclerotic, mycotic,bifurcational)
Prioraneurysm treatment witheitherendovascular (stenting, coiling)orsurgical(clipping) techniques
•Endovascular treatment assisted withcoilsorintracranial stents
•Significant orsevereallergytointra-arterial contrastmediumuncontrolled bypre-procedure
medications
•Severekidneydisease(e-GFRc60)
•Subjects notwilling(orable)toattendpostFDSinsertionstandard-of-care followupclinicvisits
requiring DSA,headMRIorCTAimaging
•Subjectparticipates inapotentially confounding drugordevicetrialduringthecourseofthestudy.
•Subjectmeetsanexclusion criteriaaccording tonationallaw(e.g.age,pregnant woman,breast
feedingwoman)
4.3.2.Enrollment andduration
Subjects areconsidered tobeenrolled inthestudyaftertheyhavesignedtheinformed consentform.
Thesubjects willbefollowed-up at6and12monthsaccording toregularclinicalstandard ofcare.
Thetotalduration ofthestudyisexpected totakeapproximately 2.5years.Patientenrollment willtakeplace
between March2018andSeptember 2019.Eachsubjectwillbeinthestudyfor1year(follow-up).
4.3.3.Number ofsubjects
Intotal120subjects willbeenrolled inthestudy.Theenrollment periodisexpected tolastfor1year.
Seesection5Statistical considerations formoredetailsonthenumberofsubjects.
4.3.4.Subjectwithdrawal ordiscontinuation
Subjects canwithdraw informed consentatanytimeduringtheclinicalinvestigation. Therearenospecific
criteriaforsubjectwithdrawal ordiscontinuation.
FormlDXCT-0302018 revOGI2016Feb01 Philips’proprietary Information. unauthorized useisprohibited
Philips Post-Market ClinicalStudyPlan XCY610-130253
ICTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page13of23
4.4.Procedures
Physician investigators participating inthisstudyareexpected tofollowtheirnormalclinicalpractice in
enrolling, treatingandfollowing patientswithintracranial aneurysms thatareamenable totreatment withflow
diverterstents.Noadditional procedures arerequired ofpatients inordertoparticipate inthisobservational
study.
Pie-Screening
Patientspresenting withintracranial saccularaneurysm(s) willbeevaluated bytheneurointerventional team,
inaccordance withinstitutional practice, toestablish anappropriate treatment planbasedonthepatient’s
medicalcondition andavailable diagnostic screening procedures priortorecruitment inthestudy.Morethan
oneaneurysm inasinglepatientmaybetreated,butonlythetargetaneurysm(s) treatedwithFDSdevices
initiallywillbeconsidered aspartofthisstudy.Iftreatment oftheaneurysm withtheFDSisdeemed
appropriate, theinstitution’s guidelines regarding theirethicscommittee andinformed consentprocess will
befollowed.
Screening
Afterobtaining theconsentform(s)approved bythelocalresearch ethicsboard(REB),theprincipal
investigator willscreenthepotential investigation subjects fortheCAROstudy.Theprincipal investigator or
hisdelegates onthestudyteamwillenterdatainapre-designed e-CRF.Thiswillincludepatient
demographics, relevantpastmedicalandsurgicalhistory,andspecifictargetaneurysm dataalongwithpre
procedurallscreening imagingdetails.
Onlypatientswhomeetallinclusion andnoneoftheexclusion criteriawillqualifyforthisstudy.The
measurement andsizeofeachaneurysm willbeverifiedbytheprincipal investigator. Ifthesizeofthe
aneurysm isacceptable, thenitwillbeincluded inthestudy.Itisrecommended thatthismeasurement
shouldbedonewithin180daysbeforetheprocedure.
IndexProcedure andDischarge
Theinvestigator willproceed withstandard ofcareprocedures onthedayofIndexProcedure (i.e.FDS
insertion) forthetargetaneurysm(s). Then,endovascular treatment procedure detailsshouldbeprovided
underthe“INDEXPROCEDURE &DISCHARGE” fieldforeacheligiblepatient.
Bloodflowvelocity willbecalculated usingthededicated software AneurysmFlow (PhilipsHealthcare, Best,
TheNetherlands), whichwillbeinstalled onstandard ofcareimagingequipment. Forthispurpose, digital
subtraction angiograms willbeacquired duringtheprocedure; justbeforeandrightafterplacement ofthe
FDS.
Calculation ofbloodflowvelocity willbeperformed automatically ontheAneurysmFlow software. The
operator willhaveaccesstotheresultsofthecalculation inaddition toalloftheregularinformation thatisat
his/herdisposal duringroutineclinicalpractice.Therearenoadditional devicesormedications requiredfor
thestudy.TheAneurysmFlow softwareusesstandard-of-care 2DDSAand3D-RAimagesequences to
determine thisflowinformation. Allrawimagesequences willbestoredforfuturereference.
Figure 1showstheworkflow forusingtheAneurysmFlow software inthisstudy.
FormIDXCT.0302D18 rov0S?2016Feb01 PhIIrpsproprietary Information, unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page14of23
Standard
.f&Jowup
3,6and12months
[Aneurysm
Ithrornbo_J
Instep1a3Drotational angiogram (3D-RA) willbeperformed intheneuro-interventional suitewiththex-ray
C-armtoacquirea3Dimagevolumeoftheaneurysm anatomy tobetreated.Fromthis3D-RA,anoptimal
viewinganglefortheC-armwillbedetermined toobtaingoodflowinformation. Thisangleshouldshowthe
parentartery,aneurysm neckandaneurysm itselfclearlywithoutanyoverlap.The3D-RAwillalsohelpto
determine agoodC-armviewingangletohelppositionanddeploytheFDSacrosstheaneurysm.
InStep2a2DDSAx-rayrunwithcontrastagentinjection (i.e.advisedinjectionrate1,5to2cc/s)willbe
acquired attheoptimalC-armviewingangledetermined bythe3D-RAscantoobtaindynamic bloodmotion
information beforeFDSdeployment atthelocationoftheaneurysm. Iftheinitialcontrastagentinjectionwas
insufficient, theinjection willbealteredandrepeated withanotherDSAruntoobtainhighqualityimage
information. TheFDSwillthenbeplacedatthelocationoftheaneurysm.
InStep3,afterFDSdeployment, asecondDSArunwithcontrastagentwillbeacquired (i.e.injectionrate
=1.5to2cc/s)attheoptimalC-armviewingangledetermined fromthe3D-RAtoqualitatively evaluate blood
motionintheregionoftheaneurysm afterdeployment oftheADS.TheC-armangleandinjectionrateofthis
secondDSArun(postFDSdeployment) mustbethesameasthefirstDSArun(preFEDSdeployment). The
2DSArunsandthe3D-RAimagevolume willautomatically besenttotheAneurysmFlow workstation right
aftertheyareacquired. IftheFDSisballooned afterplacement, thephysician isaskedtorepeatStep3after
ballooning.
InStep4aroutineVasoCTscan,whichisanother3Drotational x-rayC-armscan,willthenbeperformed
withthex-rayC-armintheneuro-interventional suitetoevaluate the3Dapposition ofthedeployed FDSwith
respectthevesselwall.
Theregionofinterestaroundtheaneurysm andthecorresponding arterialsegment fromwhichithas
developed willbeautomatically segmented bytheAneurysmFlow software, butmanualcontrolsareavailable
inthesoftware ifmodifications totheanatomical segment ofinterestaredesiredbytheinterventionalist.
Thesemodifications canbeperformed byanappropriately trainedstudymember. Thesoftware willthen
automatically calculate theflowparameters oftheaneurysm bothbeforeandafterFDSdeployment, along
withtheMAFAratio.
Forthisstudy,theoperator willhavethechoiceofselecting whichtargetaneurysms areamenable toFDS
treatment. Patientsthathavesingleormultipletargetaneurysms thataresuitableforFDStreatment asa
firsttreatment stepwouldbeacceptable forthisstudy.Eachtargetaneurysm inthepatientwillhavea
separate CRFsub-form tofillout.Additionally, eachtargetaneurysm sub-form canbefurtherdividedinto
severalFDSsub-forms toaccountformultipleflowdiverters, ifneeded.Tosummarize, ifthepatienthas
morethanonetargetaneurysm and/orneedsmorethanoneflowdiverterperaneurysm, thenasub-form on
theCRFwillneedtobefilledoutforeachaneurysm andforeachFDSused.
AsshowninFigure1,ifatargetaneurysm istreatedwithaFDS(ormorethanone)initially,andisthen
treatedusinganotherapproach (suchascoiling)thenthistargetaneurysm canremainincludedaspartof
thestudy.However, ifatargetaneurysm istreatedusinganon-FDS approach initially(suchaswithcoiling),
followed byplacement ofanFDSorotherapproach, thentheaneurysm willbeexcluded fromthestudy.Flow/MAFAL
1analysis
FormID:XCT-a302018 rev0612016 Feb01 Philips’proprietary information. unauthorized useIsprohibiteth
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARD Revision: 2.0
•Status:Approved Amulticenter observational cohortstudy Page15of23
TheMAFAratiowillbecalculated aftertheplacement ofeachFDS.ForeachFDS,thisratiowillbe
determined withtheflowinformation beforeanystentswereplacedandalsowiththeflowinformation after
eachFDSwasplaced.ThefinalMAFAratiowillbecalculated usingtheflowinformation beforeanyFDS
deviceswereplacedandusingtheflowinformation afterthelastFDSwasplaced.Clinicalandimaging
outcomes ofaprocedure willbeassessed usingacombination oftheflowmetricscalculated bythe
AneurysmFlow softwareavailable totheoperator duringinterventional treatment inaddition toinformation
thatisroutinely acquired duringFDSplacement. Thisinformation acquiredacrossthepatientpopulation in
thestudywillalsocontribute todetermine morepreciseMAFAratiothresholds toimproveprediction of
complete aneurysm occlusion afterFDSplacement. Thisstudywillnotmakeanyrecommendation onpatient
management orontreatment strategy. Also,thissoftware willnotdisruptstandard-of-care workilow forthe
interventionalist.
Follow-Ups (6and12months)
AllregistrypatientstreatedwithFDSareexpected tofollowtheirroutineposttreatment clinicalvisits,which
willincludeastandard-of-care headimaging(e.g.CTA,MRAand/orDSA)testtoclassifyaneurysm
occlusion (i.e.Raymond-Roy Occlusion Classification I(Royeta!.,1997))at6months(±49days)and12
months(±49days).Duringthe6and12monthfollowupvisits,patientmedicalchartswillbeaccessed to
collectadverseevents(ifapplicable) anddocument anypost-treatment neurological deterioration
(neurological assessment, mRsscale).De-identified data(i.e.clinicalnotes,imagingreportsetc.)willbe
entered intherelevante-CRFsections.
Follow-up visitStartvisitwindow Targetdate Endvisitwindow
l(dayspost-procedure) (dayspost-procedure) (dayspost-procedure)
6-months 134 183 225
12months 316 365 414
Adverse Events
All(serious)adverseevents(i.e.re-operations, rupturesanddeaths)whether ornotrelatedtothe
investigational devicewillbecollected andreported conform localrulesandregulations.
4.5.Monitoring Plan
Monitoring willbeperformed byatrainedpersonappointed byPhilipstoensurecompliance withthe
investigation plan,applicable nationalregulations andinternational standards, patientsafetyanddata
validity.TheSponsor maydesignate oneormoreindividuals tomonitortheprogress ofaclinicalstudy.The
Sponsormayalsodelegate themonitoring responsibilities toathirdparty.However, theSponsorremains
ultimately responsible fortheconductofthestudy.TheInstitution isresponsible fortheappropriate de
identification ofsubjectdata.Theinvestigational siteshouldprovideaccesstothesourcedataofthe
subjects.
Allregulatory documents (e.g.MEC/IRB approval, contracts, etc.)willbereviewed foreachactively
participating center.
Thefirstvisitwilloccurassoonaspossibleafterthefirstsubjectisenrolledateachstudysite.The
monitoring schedule isbasedonthefollowing considerations: enrollment rate,studycompliance atthe
center,magnitude ofdatacorrections required, studystage(e.g.start-uporfollow-up), complexity ofthe
investigation, IRB/MEC request,audit/inspection.
Criticaldataandprocesses willbemonitored forthisstudypriortoclinicalreportcompletion basedonarisk
basedmonitoring approach. Dependent ontheriskahighorlowersamplewillbemonitored.
Themonitorwillreviewcriticalclinicaldatathateffectstudyendpoints. Datacollection forreasonsotherthan
tosupporttheprotocol-defined endpoints willnotbemonitored.
Aclose-out visitforsitesthathaveenrolledsubjects willbeconducted oncethesitehascompleted collecting
dataforthestudy.
Namesofthemonitor(s) canbefoundinAppendix IIofthisprotocol. Anupdateofthislistcanbeprovided to
thesiteunderseparate cover.
FormID:XCT.0302018 revO6I2016Feb01 Philips’propr,etary røormation, unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page16of23
5.STATISTICAL CONSIDERATIONS
Baseline patientcharacteristics andfollow-up resultswillbesummarized descriptively usingfrequencies and
percentages orsummary statistics likemeansandmedians (including confidence intervals andinterquartile
ranges). Multipleimputation methods willbeusedtocorrectformissingdata(Rubin,1987).
5.1.Sample SizeJustification
Thetotalsamplesizeforthisstudywascalculated usingthefollowing formulas forReceiver Operating
Characteristics Studies(Obuchowski, 2000):
I:../II.(I792 (1±I1n)+
nfl—
whereV(s)isthevariance function of8givenby:
V(øi=(I).III)!)hi.11)(%l+S’I.1jSJ/n)
i.e.,thevariance ofSisequaltoV(S)/nD; A=0—1(0) x1.414;0—1istheinverseofthecumulative normal
distribution function; xistheratioofthenumberofcontrolpatients(nC)tothenumberofdiseased patients
(nD)inthestudysample(i.e.,K=nC/nD); 0istheconjectured areaundertheROCcurve(underthe
alternative hypothesis); zaistheupperathpercentile ofthestandard nomialdistribution, whereaisthetype
Ierrorrate(usuallya=0.05);and43istheupperthpercentile ofthestandard normaldistribution, wheref3
isthetypeIIerrorrate(often3=0.10or0.20).
Assuming k0.25(i.e.,4timesasmanyoccluded aneurysms thannon-occluded aneurysms after1year),a
fairAUCof0.70,atypeIerrorof0.05andatypeIIerrorrateof0.10(power0.90),atotalof100subjects
shouldbeincluded inthestudy.Thistotalnumberof100subjectsalsoaccommodates thepre-planned
explorative multivariate analysis allowinginclusion of8candidate predictors including AneurysmFlow (Peduz
etal.1996).Allowing foranexpected drop-out rateof15%weaimtoincludeatotalof120patientsintothe
study.
Anydeviation fromtheplannedanalysisdescribed belowwillbedocumented withjustification inthefinal
clinicalendreport.
5.2.GeneralConsideration
Theprimaryanalysis oftheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 12months
afterfiow diverterplacement willbeperformed including allsubjectswhounderwent treatment. Baselinepatient
characteristics andfollow-up resultswillbesummarized descriptively usingfrequencies andpercentages or
summary statistics likemeansandmedians (including confidence intervalsandinterquartile ranges). Multiple
imputation methods willbeusedtocorrectformissingdata(Rubin,1987).Allstatistical analysis willbe
performed usingRstatistical software (www.https:l/www.r-project.org)
5.3.Subjectdisposition
Subjectdisposition, including thetotalnumberofsubjectsevaluated willbepresented. Inaddition, alisting
willbeprovided withthereasonsforwhythesubjectwasnotevaluated.
5.4.Primaryobjective
Objective
Toassesstheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 12monthsafterflow
diverterplacement.
Endpoint
FormID:XCT-0302018 revOGI2016Feb01 Philips’proprietary Information, unauthorized useisprohibited,
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page17of23
Theprimaryendpoint istheprognostic value(i.e.c-statistic including confidence intervals) oftheMAFAratio
withrespecttofullaneurysm occlusion (i.e.Raymond-Roy Occlusion Classification I(Royetal.,1997)on
standard-of-care headimaging) 12monthsafterflowdiverterplacement.
Experimental design
Wewilluselogisticregression analysis toevaluate theunivariate predictive association between theindex
test(i.e.theMAFAratio)andcomplete aneurysm occlusion (i.e.complete occlusion yes/no)at12months
(Moonsetal.,2012).Allsubjects withcomplete follow-up willbeincluded inthisanalysis.
Presentation format
Theprimaryendpoint willbepresented usinganROCcurveincluding thec-statistic andconfidence intervals.
5.5.Secondary objectives
5.5.1.Secondary objective: Predictive valueat6monthsfollow-up
Objective
Toassesstheprognostic valueoftheMAFAratioforpredicting fullaneurysm occlusion 6monthsafterflow
diverterplacement.
Endpoint
Thesecondary endpoint istheprognostic value(i.e.c-statistic including confidence intervals) oftheMAFA
ratiowithrespecttofullaneurysm occlusion (i.e.Raymond-Roy Occlusion Classification I(RoyetaL,1997)
onstandard-of-care headimaging) 6monthsafterflowdiverterplacement.
Experimental design
Wewilluselogisticregression analysis toevaluatetheunivariate predictive association betweentheindex
test(i.e.theMAFAratio)andcomplete aneurysm occlusion onstandard-of-care headimagingat6months
(MoonsetaL,2012).Allsubjects withcomplete follow-up willbeincluded inthisanalysis.
Presentation format
Thissecondary endpoint willbepresented usingaROCcurvesincluding thec-statistic andconfidence
intervals.
5.5.2.Secondary objective: Optimal MAFAratiothreshold
Objective
Todetermine optimalMAFAratiothreshold.
Endpoint
Theendpoint forthissecondary analysis istheoptimalthreshold tomaketreatment decisions.
Experimental design
Todetermine theoptimalthreshold fortheMAFAratio,ROCanalysis willbeperformed. Theoptimal
threshold forclinicaldecision makingwillbedetermined usingnet-benefit analysis (MallettetaL,2012).Net
benefitincorporates estimates ofprevalence andmisclassification costs,anditisclinically interpretable since
itreflectschanges incorrectandincorrectdiagnoses whenanewdiagnostic testisintroduced.
Presentation format
Thissecondary analysis willbepresented within(thelegendof)thevariousROCcurvescomposed forthe
primaryandsecondary objectives.
5.5.3.Secondary objective: Adverse events
Objective
Toregister(serious) adverseevents(i.e.re-operations, rupturesanddeaths).
Endpoint
FormIDXCT.0302018 rev0612016Feb01 Phips’propsietary Information. Unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page18of23
Theendpoint forthissecondary analysis isthe(total)numberofadverseevents.
Experimental design
Thenumberofadverseeventswillbedescribed usingfrequencies andpercentages
Presentation format
The(total)numberofadverseeventswillbepresented intabularformat.
5.6.Exploratory objectives
5.6.1.Exploratory objective: Potential valueadditional AneurysmFlow parameters
Objective
Toevaluatethepotential valueofadditional AneurysmFlow parameters forpredicting fullaneurysm
occlusion 6and12monthsafterflowdiverterplacement.
Endpoint
Theendpoint ofthisexploratory objective istheidentification ofoneormoreadditional AneurysmFlow
parameters forpredicting fullaneurysm occlusion 6and12monthsafterflowdiverterplacement.
Experimental design
Toexplorewhichadditional AneurysmFlow parameters (e.g.maximum inflow,numberofjets)independently
contribute totheprediction of,i.e.,areassociated with,fullaneurysm occlusion 6and12monthsafterflow
diverterplacement predictor findingmethods willbeused.Thesemethods willbeappliedtotherawimaging
data,collected duringthestudy.
Presentation format
Theidentified additional AneurysmElow parameters forpredicting fullaneurysm occlusion 6and12months
afterflowdiverterplacement willbepresented inatabularform,including thestrength oftheassociation.
5.6.2.Exploratory objective: Potential ValueofAddingClinicalVariables
Objective
•Toevaluate thepotential valueofadditional clinicalvariables topredictfullaneurysm occlusion 6
and12monthsafterflowdiverterplacement usingmultivariate logisticregression.
Endpoint
Theendpoint ofthisexploratory objective isthefinalselected multivariate logisticregression modelafter
shrinkage including itsperformance measures (i.e.calibration anddiscrimination).
Experimental design
Toexplorewhichclinicalvariables have(independent) addedvalueforpredicting fullaneurysm occlusion 6
and12monthsafterflowdiverterplacement weusemultivariate logisticregression methods. Candidate
predictors (e.g.,aneurysm location,size,medication) willbeselectedbasedonliterature andexpertopinion.
Then,variableselection (i.e.backward selection usingAkaikeInformation Criteria) willbeusedtodetermine
thefinalsetofpredictors. Finally,internalvalidation andshrinkage ofthemodel(i.e.usingbootstrap methods)
willbeperformed tocorrectforoptimism. Information gainedfromthisexploratory analysiscanbeusedas
valuable inputforafutureclinicalprediction modelforaneurysm occlusion.
Presentation format
Thefinalprediction modelanditsperformance measures (i.e.calibration anddiscrimination) willbe
presented usinggraphs(i.e.calibration curveandROCcurve)andtables(i.e.modelincluding interceptand
regression coefficients, c-statistic andcalibration slope).
6.DATAMANAGEMENT
Ane-CRFwillbeusedtocollectde-identified medicalhistory,subjectsdemographics, procedure related
information, protocoldeviations, adverseeventsanddevicedeficiencies.
FormIDXCT.D302016 ,evO6f2016Feb01 Philipsproprietary informatron. Unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page19of23
Thee-CRFwillbeusedfordatareview,datacleaningandissuingandresolving queries.Thise-CRFisa
web-based e-CRFwhichispassword protected andis21CFRpart11compliant. Attheendofthestudythe
datawillbestoredasafrozendatasetandwillberetained.
Rawimagedataiscollected directlyfromthedetector, andtherefore isfreefromanysubjectinformation. All
otherexported datawillbede-identified. Thisdatawillbecollected andstoredinasecurelocation.
6.1.Retention period
Theinvestigator shallmaintaintherecordsrelatedtothisstudyduringtheinvestigation andforaperiodof2
yearsafterthelatterofthefollowing twodates:Thedateonwhichthestudyisterminated orcompleted, or
thedatethattherecordsarenolongerrequired forpurposes ofsupporting apremarket approval application
intheUSoranoticeofcompletion ofaproductdevelopment protocol. Orlongerifnationalregulation
requiresthis.
Philipswillmaintain therecordsforthesameperiodastheinvestigator orforaperiodofdeviceEndofLife
(EoL)plus15years,whichever islater.
Thesponsorandprincipalinvestigator shalltakemeasures topreventaccidental orpremature destruction of
thesedocuments.
7.AMENDMENTS TOTHECLINICAL STUDY PLAN
Amendment totheClinicalinvestigational planandtheinformed consentshallbenotifiedto,orapproved by
theMedicalEthicsCommittee (MEC)andregulatory authority. Theversionnumberanddateofamendments
shallbedocumented. Significant changes(suchasdevicemodifications, studyprocedures) shallbe
discussed withtheprincipalinvestigator priorapproval. Allchanges willbedocumented withajustification
anddescribed inthelatestversionoftheClinicalInvestigation Plan.
8.DEVIATIONS FROMTHECLINICAL STUDY PLAN
Theinvestigator isnotallowedtodeviatefromtheclinicalstudyplanortoenrollsubjectsthatdonotcomply
withallinclusion andexclusion criteria.Underemergency circumstances, deviations fromtheclinicalstudy
plantoprotecttherights,safetyandwell-being ofhumansubjects mayproceedwithoutpriorapproval ofthe
sponsorandtheMEC.Suchdeviations shallbedocumented andreported tothesponsorandtheMECas
soonaspossible.
Alldeviations fromtheclinicalstudyplanwillbedocumented withdate,subject,reason,actionstakenandif
thedeviation affectssubjects rights,safetyandwell-being orthescientific integrityoftheclinicalstudy,The
deviation shallbenotifiedtotheSponsorassoonaspossible viathee-CRF.Deviations willbereviewed by
thesponsorandincaseofseriousorrepetitive deviations acorrective actionplanmayrepresent aneedto
initiateacorrective actionplanwiththeprincipal investigator. Insomecases,necessitate suspension of
enrollment atthesiteorultimately theprincipalinvestigator willbedisqualified.
9. DEVICE ACCOUNTABILITY
Thedeviceusedinthisstudy(i.e.AneurysmFlow) ismarketreleased, CEmarkedandcleared inUS,
CanadaandArgentina. AneurysmFlow isnotregulated inIndiaasasoftware medicaldevice.Therefore no
deviceaccountability (e.g.documented returnanddisposal) willbeperformed.
10.STATEMENTS OFCOMPLIANCE
Thisclinicalstudyshallbeconducted inaccordance withtheclinicalstudyplan,andwiththeethical
principles thathavetheiroriginintheDeclaration ofHelsinkiandallapplicable regionaland/ornational
regulations.
Furthermore, inEuropethisclinicalInvestigation shallbeconducted inaccordance with
theInternational Standards ISO14155Clinicalinvestigation ofmedicaldevicesforhumansubjects —Good
clinicalpracticeandtheMedicalDeviceDirective (MDD).Studiesconducted inCanadashallfollowaswell
theISO14155Clinicalinvestigation ofmedicaldevicesforhumansubjects —Goodclinicalpractice.
FormID:XCT-0302018 revo6!2016 Feb01 PhJIips’proprLetary InformatIon. tInauthorzed useIsproNbited.
I •I
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page20of23
Furthermore allinvestigators willcomplete financialdisclosures, asoutlined inthe21CFRpart54andwill
alsocomplywithpart11.Investigators located intheUSshallfollowapplicable requirements toclinical
investigations andGCP:21CFRpart50,56and812.
Clinicaltrialsconducted inIndiashallfollowtheEthicalGuidelines issuedbyIndianCouncilofMedical
Research.
Thisstudyshallnotbestartedpriortoobtaining afavorable opinionfromaMedicalEthicsCommittee
(MEC)/Institutional ReviewBoard(IRB)andregulatory authority, ifrequired. Anyadditional requirements
imposed bytheMEC/IRB andregulatory authority shallbefollowed.
Insurance shallbeprovided forthesubjects participating inthisclinicaltrialaccording tolocallaw.
11.INFORMED CONSENT PROCESS
Informedconsent willbeobtained fromeverysubjectinwritingbytheInvestigator orhisauthorized designee
beforetheclinicalstudyisstarted.
Thesubjectwillbeinformed bothorallyandinwritingaboutallaspectsthatarerelevant tothesubject’s
decision toparticipate intheclinicalstudy,including theclinicalstudyprocedures. Amplelimeshouldbe
provided forthesubjecttoreadandunderstand theinformed consentformandtoconsider participation. The
informedconsent willincludepersonally datedsignatures ofthesubjectandtheprincipalinvestigator oran
authorized designee responsible forconducting theinformed consentprocess. Acopyofthesignedand
datedinformed consentformandanyotherwritteninformation willbeprovided tothesubject.
Subjects whoareunwilling toprovideinformed consent willnotbeincluded intheclinicalstudy.
Ifnewinformation becomes available thatmightsignificantly affectthesubject’s futurehealthandmedical
care,itshallbeprovided tothesubjects inwrittenform,Ifrelevant,subjectshallbeaskedtoreconfirm their
continuing informed consent inwriting.
11.1.Subjectunabletoreadorwrite
Informed consentshallbeobtained throughasupervised oralprocess ifasubjectisunabletoreadorwrite.
Anindependent witnessshallbepresentthroughout theprocess.Thewritteninformedconsentformandany
otherinformation shallbereadaloudandexplained totheprospective subjectorhis/herlegallyauthorized
representative and,whenever possible, eithershallsignandpersonally datetheinformed consentform.The
witnessalsosignsandpersonally datestheinformed consentformattesting thattheinformation was
accurately explained andthatinformed consentwasfreelygiven.
12.SAFETY REPORTING
Thefollowing eventshouldbereported toPhilipsforMedicalDeviceReporting (MDR)according to21CFR
part803:Deathsandseriousinjuriesthatadevicehasormayhavecausedorcontributed to.Causedor
contributed meansthatadeathorseriousinjurywasormayhavebeenattributed toamedicaldevice,orthat
amedicaldevicewasormayhavebeenafactorinadeathorseriousinjury,including eventsoccurring asa
resultof:(1)Failure;(2)Malfunction; (3)Improper orinadequate design;(4)Manufacture; (5)Labeling; or(6)
Usererror.MedicalDeviceReporting shallbereported totheregularPhilipsHealthcare customer feedback
system, i.e.contactthelocalHelpdesk (optional toaddphonenumber e.g.+31402764777) toreportthese
events.AlsoreportthesetotheClinicalScientist(seeAppendix IIListofmonitor(s)/clinical scientist).
13.EARLYTERMINATION ORSUSPENSION OFTHECLINICAL STUDY
Therearenoprovisions orinterimanalyses plannedthatcanresultinanearlytermination ofthetrial.
Seriousorrepetitive occurrence ofdeviations fromstudyprotocolornon-compliance withregulations may
alsobereasonforearlytermination orsuspension ofastudysite.
FormIDXCT-0302018 rev06/2016Feb01 PIliFips’proprietary information. Unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page21of23
14.PUBLICATION POLICY
Itistheintention oftheinvestigator andsponsortosubmittheclinicalstudydataforpublication. Priorto
submission, claimsonintellectual property willbeassessed. Thisstudywillalsoberegistered on
clinicaltrial.gov beforefirstenrollment.
15.ABBREVIATIONS USED
•nofab$4..
3D-RA 3DRotational Angiogram
CE Conformite Européenne (European Conformity)
CAR CodeofFederalRegulation
CRF CaseReportForm
DSA DigitalSubtraction Angiography
e-CRF Electronic CaseReportForm
FDS FlowDiverterStent
IA Intracranial Aneurysm
IFU Instructions forUse
IRB Institutional ReviewBoard
ISO International Organization forStandardization
MAFA MeanAneurysm FlowAmplitude
MEC MedicalEthicCommittee
MDD MedicalDeviceDirective
MDR MedicalDeviceReporting
16.REFERENCES
Bonnefous, 0.,Pereira, V.M.,Quared, R.,Brina,0.,Aerts,H.,Hermans, R.,vanNijnatten, F.,Stawiaski, J.
andRuijters, D.(2012)‘Quantification ofarterialflowusingdigitalsubtraction angiography’, MedicalPhysics,
39(10),p.6264. doi:10.1118/1.4754299.
Bruno,G.,Todor,R.,Lewis, I.andChyatte, D.(1998)‘Vascular extracellular matrixremodeling incerebral
aneurysms’, 89,pp.431—440.
Krings,T.,Mandell, DM.,Kiehl,T.,Geibprasert, S.,Tymianski, M.,Alvarez, H.,Karel,G.andHans,F.
(2011)‘Intracranial aneurysms: fromvesselwallpathology totherapeutic approach’, NaturePublishing
Group.NaturePublishing Group,7(10),pp.547—559. doi:10.1038/nrneurol.2011.136.
Lylyk,P.,Miranda, C.,Ceratto, R.,Ferrario, A.,Scrivano, E.,Luna,H.R.,Berez,A.L.,Tran,Q.,Nelson,P.
K.andFiorella, D.(2009)‘Curative Endovascular Reconstruction OfCerebral Aneurysms WithThePipeline
Ernbolization Device:TheBuenosAiresExperience’, 64(4),pp.632—643. doi:
10.1227/01 .NEU.00003391 09.98070.65.
Malleti,S.,Halligan, S.,Thompson, M.,Collins,S.S.andAllman, D.5.(2012)‘Interpreting diagnostic
accuracy studiesforpatientcare’,3999(July), pp.1—7.doi:10.1136/bmj.e3999.
Moons, K.S.M.,DeGroot,.1.A.H.,Linnet,K.,Reitsma, J.B.R.andBossuyt, P.M.M.(2012)‘Quantifying
theaddedvalueofadiagnostic testormarker’, ClinicalChemistry. doi:10.1373/clinchem.2012.182550.
Obuchowski, N.A.(2000)‘SampleSizeTablesForReceiver Operating Characteristic Studies’, (September),
pp.603—608.
Peduz,P.,Concato, J.,Kemper, E.,Holford,T.R.andFeinstein, A.R.(1996)‘StudyoftheNumberof
EventsperVariable inLogisticRegression Analysis’, 49(12),pp.1373—1379.
Pereira, V.M.,Bonnefous, 0.,Ouared, R.,Brina,0.,Stawiaski, J.,Aerts,H.,Ruijters, D.,Narata,A.P.,
Bijlenga, P.,Schaller, K.andLovblad, K.0.(2013)‘ADSA-based methodusingcontrast-motion estimation
fortheassessment oftheintra-aneurysmal flowchanges induced byfiow-diverter stents’,American Journal
FarmID:XCT-0302018 revOGf2DlG Feb01 Philips’proprietary Information, unauthorized useisprohibited.
Philips Past-Market ClinicalStudyPlan XCY61O-1 30253
IGTSystems 2018Apr06
CARO Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page22of23
ofNeuroradiology, 34(4),pp.808—815.doi:10.3174/ajnr.A3322.
Pereira, V.M.,Quared, R.,Brina,0.,Bonnefous, 0.,Satwiaski, J.,Aerts,H.,Ruijters, D.,vanNijnatten, F.,
Perren,F.,Bijienga, P.,Schaller, K.andLovblad, K.-0.(2014)‘Quantification ofinternalcarotidarteryflow
withdigitalsubtraction angiography: validation ofanopticalflowapproach withDopplerultrasound.’, AJNR.
American journalofneuroradiology, 35(1),pp.156—63. doi:10.3174/ajnr.A3662.
Roy,D.,Raymond, J.,Bouthillier, A.,Bojanowski, M.W.,Moumdjian, R.andL’Esperance, G.(1997)
‘Endovascular treatment ofophthalmic segment aneurysms withGuglielmi detachable coils’,American
JournalofNeuroradiology, 18(7),pp.1207—1215.
Rubin,D.B.(1987)MultipleImputation forNonresponse inSurveys.
APPENDIX ILISTOFINVESTIGATORS ANDSITES
Updateofthislistcanbeprovided tothestudysiteunderseparate cover.
Table1:ClinicalCoordinating Investigator
Name
Dr.RicardoHanel BaptistMedicalCenterJacksonville
800Prudential Drive
Jacksonville, Fl32207__________________________
USA
Table2:Listofprinciple Investigators
me
TorontoWestern Hospital
Department ofMedicalImaging
399Bathurst St.
TorontoONM5T258
Canada‘nsite(s)
Dr.VitorMendesPereira
Dr.CivanIslak IstanbulUniversitesi Cerrahpaa TipFakUltesi
34098Cerrahpaa-Fatih Istanbul
Turkey
Dr.AjayWakhloo UMassMemorial MedicalCenter -University Campus
55LakeAvenueNorth
Worcester, MA01655
USA
Dr.Santhosh Joseph SriRamachandra MedicalCentre
No.1Ramachandra Nagar,Porur
Chennai, TamilNadu,
India600116
Dr.PedroLylyk ENERI
Av.delLibertador 6647
(C1428ARJ) CABA,Argentina
FormID:XCT-0302018 reva6/2016Feb01 Philipsproprietary information. Unauthorized useisprohibited.
Philips Post-Market ClinicalStudyPlan XCY610-1 30253
IGTSystems 2018Apr06
CARD Revision: 2.0
Status:Approved Amulticenter observational cohortstudy Page23of23
APPENDIX II:LISTOFMONITOR(S)/CLINICAL SCIENTIST
Updateofthislistcanbeprovided totheInvestigational sitesunderseparate cover.
Table3:Listofmonitor/clinical scientist
JorisdeGroot Best,TheNetherlands
ClinicalTrialManager Telephone: +31611645166
ioris.ah.degroot(amhiIips.com
MartijnvandeGiessen Singapore, WA,USA
ClinicalScientist Telephone: 6596308211
martUnvan.de.giessen(äph ilips.com
MartinevanAlfen Boston, MA,USA
ClinicalScientist Telephone: +16177350209
martine.van.alfen@philips.com
FormID’XCI-0302018 reva6)2016Feb01 Philips’propdetary Irifonnation. Unauthorized useisprobbted.